ORGANOGENESIS HOLDINGS INC
NASDAQ: ORGO (Organogenesis Holdings Inc.)
Last update: 2 days ago, 11:56PM5.15
0.03 (0.59%)
Previous Close | 5.12 |
Open | 5.08 |
Volume | 314,173 |
Avg. Volume (3M) | 859,682 |
Market Cap | 653,318,720 |
Price / Sales | 1.40 |
Price / Book | 2.54 |
52 Weeks Range | |
Earnings Date | 7 Aug 2025 |
Profit Margin | -3.46% |
Operating Margin (TTM) | -23.28% |
Diluted EPS (TTM) | -0.160 |
Quarterly Revenue Growth (YOY) | -21.20% |
Quarterly Earnings Growth (YOY) | 289.40% |
Total Debt/Equity (MRQ) | 11.58% |
Current Ratio (MRQ) | 4.12 |
Operating Cash Flow (TTM) | 4.43 M |
Levered Free Cash Flow (TTM) | -4.36 M |
Return on Assets (TTM) | 0.70% |
Return on Equity (TTM) | -4.92% |
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
Stock | Organogenesis Holdings Inc. | Bullish | Bullish |
AIStockmoo Score
Analyst Consensus | 1.5 |
Insider Activity | NA |
Price Volatility | -1.5 |
Technical Moving Averages | 0.0 |
Technical Oscillators | 4.0 |
Average | 1.00 |
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Investment Style | Small Core |
% Held by Insiders | 46.49% |
% Held by Institutions | 54.09% |
52 Weeks Range | ||
Median | 9.00 (74.76%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Cantor Fitzgerald | 08 Aug 2025 | 9.00 (74.76%) | Buy | 4.56 |
15 Jul 2025 | 7.00 (35.92%) | Buy | 4.03 |
No data within this time range.
Date | Type | Details |
---|---|---|
27 Aug 2025 | Announcement | Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September |
07 Aug 2025 | Announcement | Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results |
22 Jul 2025 | Announcement | Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025 |
15 Jul 2025 | Announcement | Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |